Download Publication
2026 China Regulations Readiness Checklist
As China continues to evolve its pharmaceutical regulatory landscape, organizations operating within or in partnership with the Chinese market must proactively adapt to remain compliant and competitive. The National Medical Products Administration (NMPA) has outlined ambitious reform goals extending to 2027 and 2035, emphasizing innovation, quality, and international harmonization. This checklist is designed to help Rx-360 members and other stakeholders navigate the complexities of these reforms by providing a structured approach to readiness and compliance.
From monitoring regulatory updates to strengthening supply chain security, each section of this checklist highlights critical actions that companies should take to align with China’s evolving expectations. Whether you’re a market authorization holder, contract manufacturer or supplier, or part of a global regulatory affairs team, this tool will support your strategic planning and operational execution in the face of regulatory transformation.